stoxline Quote Chart Rank Option Currency Glossary
  
Idera Pharmaceuticals, Inc. (IDRA)
0.425  -0.127 (-23.04%)    01-17 16:00
Open: 0.4768
High: 0.51
Volume: 371,878
  
Pre. Close: 0.5522
Low: 0.4201
Market Cap: 0(M)
Technical analysis
2023-03-31 4:19:33 PM
Short term     
Mid term     
Targets 6-month :  5.51 1-year :  6.35
Resists First :  4.72 Second :  5.44
Pivot price 4.26
Supports First :  3.56 Second :  2.97
MAs MA(5) :  4 MA(20) :  4.41
MA(100) :  5.71 MA(250) :  6.94
MACD MACD :  -0.4 Signal :  -0.4
%K %D K(14,3) :  12.3 D(3) :  10.7
RSI RSI(14): 37.2
52-week High :  16 Low :  0.42
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ IDRA ] has closed below the lower bollinger band by 17.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ IDRA ] is to continue within current trading range. It is unclear right now based on current values. 72.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.21 - 4.24 4.24 - 4.26
Low: 4.07 - 4.09 4.09 - 4.11
Close: 4.12 - 4.16 4.16 - 4.2
Company Description

Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

Headline News

Mon, 14 Nov 2022
Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update - GlobeNewswire

Wed, 28 Sep 2022
Idera Pharmaceuticals Acquires Aceragen - GlobeNewswire

Tue, 09 Aug 2022
Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results - GlobeNewswire

Tue, 17 May 2022
Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam ... - GlobeNewswire

Thu, 31 Mar 2022
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update - GlobeNewswire

Tue, 14 Dec 2021
Idera Pharmaceuticals Announces Tilsotolimod Updates - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 0 (M)
Held by Insiders 0 (%)
Held by Institutions 0 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly -0.12
EPS Est This Year -0.48
EPS Est Next Year -0.5
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) -0.18
Sales Per Share 0
EBITDA (p.s.) -0.37
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2018-07-29
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android